CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced that eight abstracts on ferumoxtytol, its lead product candidate, have been accepted for presentation at the American Society of Nephrology (ASN) meeting to be held in San Francisco, CA, November 1-5, 2007.
